Johnson & Johnson said on Friday it was preparing to resume a large clinical trial of its experimental COVID-19 vaccine in the United States after an independent safety panel recommended enrollments for the study.
Last week, the company paused its late-stage trial after a study participant became ill.
J&J at the time said it was not clear if the volunteer had received the vaccine or a placebo and that it would take at least a few days for an independent data and safety monitoring board to evaluate the illness.
Reporting by Dania Nadeem and Vishwadha Chander in Bengaluru; Editing by Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.